Topical Treatment of Psoriasis Vulgaris in New Zealand

Research Review E-Learning Module

Begin

Topical Treatment of Psoriasis Vulgaris in New Zealand

This Research Review E-Learning Module is intended for New Zealand nurses and nurse practitioners. Content includes an overview of psoriasis vulgaris including presentation, impacts on patients and clinical assessment. Treatment protocols are discussed with a focus on topical therapies. Particular emphasis is given to a new aerosol foam spray containing a fixed-dose combination of calcipotriol and betamethasone diproprionate. This E-Learning Module is based on the Research Review Educational Series publication ‘Topical Treatment of Psoriasis Vulgaris in New Zealand’.

Before starting the module please read the Educational Series publication, accessed through the link below:

CLICK HERE
to access the quiz source material
Educational Series - Topical Treatment of Psoriasis Vulgaris in New Zealand

The PDF can be viewed on screen or saved and printed through the link above. 

This E-Learning Module covers:

  • Prevalence, complications and impacts of psoriasis
  • Clinical features of psoriasis
  • Assessment & differential diagnoses for psoriasis
  • General treatment considerations
  • Protocols for treatment with topical therapies
  • Calcipotriol/betamethasone diproprionate aerosol foam spray

Learning outcomes

After completing this module you should have an improved understanding of the:

  • Prevalence, complications and impacts of psoriasis
  • Clinical features of psoriasis
  • Assessment & differential diagnoses for psoriasis
  • General treatment considerations for psoriasis
  • Protocols for treatment of psoriasis with topical therapies
  • Calcipotriol/betamethasone diproprionate aerosol foam spray

Contributing experts

Expert commentary is provided by Dr Bruce Taylor, Senior Consultant Dermatologist at Wellington Hospital. 

Module questions have been developed by Dr Chris Tofield, who works in primary care skin cancer treatment, is clinical advisor at Bay of Plenty District Health Board, and consultant to Research Review.

Accreditation

“Topical Treatment of Psoriasis Vulgaris in New Zealand” E-Learning Module has been endorsed by The College of Nurses and has been approved for 1 hour professional development. Valid until 27 July 2022.
Further info

References

  1. LEO Pharma Ltd. Enstilar® New Zealand Datasheet. 5 October 2018. https://www.medsafe.govt.nz/Profs/Datasheet/e/EnstilarFoam.pdf
  2. Cohen SN, et al. Guidance on the diagnosis and clinical management of psoriasis. Clin Exp Dermatol 2012;37 Suppl 1:13–8.
  3. Sullivan JR, et al. Treatments for severe psoriasis. Aust Prescr 2009;2009:14–8.
  4. Menter A, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010;62:114–35.
  5. Bewley A, et al. Identifying individual psychosocial and adherence support needs in patients with psoriasis: a multinational two-stage qualitative and quantitative study. J Eur Acad Dermatol Venereol 2014;28:763–70.
  6. Burfield L, et al. Psoriasis. J R Coll Physicians Edinb 2013;43:334–8.
  7. DermNet NZ. Guidelines for the management of psoriasis. January 2020. https://dermnetnz.org/topics/guidelines-for-the-treatment-of-psoriasis/
  8. Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol 2012;26 Suppl 2:3–11.
  9. Clarke P. Psoriasis. Aust Fam Physician 2011;40:468–73.
  10. Parisi R, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013;133:377–85.
  11. Michalek IM, et al. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol 2017;31:205-12.
  12. Feldman SR. Psoriasis: Epidemiology, clinical manifestations, and diagnosis. UpToDate. Updated October 2019. https://www.uptodate.com/contents/epidemiology-clinical-manifestations-and-diagnosis-of-psoriasis
  13. National Institute for Health and Care Excellence. Psoriasis: assessment and management. Updated September 2017. https://www.nice.org.uk/guidance/cg153/
  14. Lee M, et al. Ethnicity of psoriasis patients: an Auckland perspective. N Z Med J 2014;127:73-74.
  15. Heyes C, et al. Non-infectious skin disease in Indigenous Australians. Australas J Dermatol 2014;55:176–84.
  16. Raychaudhuri SP, et al. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 2001;15:16–7.
  17. Chong HT, et al. Lifting the silver flakes: the pathogenesis and management of chronic plaque psoriasis. Biomed Res Int 2013;2013:168321.
  18. Levine D, et al. Evaluation and management of psoriasis: an internist’s guide. Med Clin North Am 2009;93:1291–303.
  19. Bhosle MJ, et al. Quality of life in patients with psoriasis. Health Qual Life Outcomes 2006;4:35.
  20. Gelfand JM, et al. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 2004;51:704–8.
  21. Korman NJ, et al. Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA. Clin Exp Dermatol 2016;41:514–21.
  22. Armstrong AW, et al. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011. PLoS One 2012;7:e52935.
  23. Rapp SR, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401-7.
  24. Cimmino MA. Epidemiology of psoriasis and psoriatic arthritis. Reumatismo 2007;59 Suppl 1:19–24.
  25. Kivelevitch D, et al. Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis. Biologics 2014;8:169–82.
  26. Kimball AB, et al. Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol 2011;25:157–63.
  27. Schön MP et al. Psoriasis. N Engl J Med. 2005;352:1899-1912.
  28. DermNet NZ 2014. Psoriasis. https://dermnetnz.org/topics/psoriasis/
  29. Menter A et al. Current and future management of psoriasis. Lancet 2007;370:272-84.
  30. Rhodes J, et al. The surface area of the hand and the palm for estimating percentage of total body surface area: results of a meta-analysis. Br J Dermatol 2013;169;76-84.
  31. Segaert S, et al. Long-term topical management of psoriasis: the road ahead. J Dermatolog Treat. 2020;24:1-10.
  32. Australasian College of Dermatologists. Treatment goals for psoriasis: The Australian Psoriasis Treatment Goals Project. The Australasian College of Dermatologists Consensus Statement. March 2017. https://www.dermcoll.edu.au/wp-content/uploads/ACD-Consensus-Statement-Treatment-goals-for-psoriasis-March-2017.pdf
  33. National Institute for Health and Care Excellence. Psoriasis overview. Updated August 2019. https://pathways.nice.org.uk/pathways/psoriasis
  34. Korman N. Comorbid disease in psoriasis. UpToDate. Updated Jan 2019. https://www.uptodate.com/contents/comorbiddisease-in-psoriasis
  35. Gottlieb AB, et al. Psoriasis comorbidities. J Dermatol Treat. 2008;19:5-21.
  36. Christophers E, et al. Psoriasis. In: Freedberg IM, et al, eds. Fitzpatrick’s Dermatology in General Medicine. Vol 2. 5th ed. New York, NY:McGraw-Hill, Inc; 1999:495-521.
  37. Auckland Regional HealthPathways. Psoriasis. Updated October 2018. https://aucklandregion.healthpathways.org.nz/index.htm
  38. Pathak S, et al. Self-management in patients with psoriasis. Psoriasis: Targets and Therapy. 2014;4:19-26.
  39. Hosseini P, et al. Investigation of the relationship between atopy and psoriasis. Postepy Dermatol Alergol. 2019;36:276-81.
  40. Santangelo C, et al. Anti-inflammatory Activity of Extra Virgin Olive Oil Polyphenols: Which Role in the Prevention and Treatment of Immune-Mediated Inflammatory Diseases? Endocr Metab Immune Disord Drug Targets. 2018;18:36-50.
  41. NPF (National Psoriasis Foundation). The Psoriasis and Psoriatic Arthritis Pocket Guide - Treatment Algorithms and Management Options. 2019. https://www.psoriasis.org/pocket-guide
  42. Menter A, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009;60:643–59.
  43. Stein Gold LF, et al. Understanding Topical Therapies for Psoriasis. Cutis. 2019;103:8-12.
  44. National Institutes for Health and Care Excellence (NICE). Psoriasis: assessment and management. 2012. www.nice.org.uk/guidance/cg153
  45. BPAC. Choosing a topical treatment for patients with chronic plaque psoriasis. 2017. https://bpac.org.nz/2017/psoriasis-2.aspx
  46. Mawson R. Top tips: psoriasis. 1 December 2015. https://www.guidelinesinpractice.co.uk/skin-and-wound-care/top-tipspsoriasis/352697.article
  47. Samarasekera EJ, Smith CH, National Institute of Health and Care Excellence, et al. Psoriasis: guidance on assessment and referral. Clin Med (Lond) 2014;14:178–82.
  48. Canadian Psoriasis Network. Prescription Topical Treatments. October 28, 2019. https://www.canadianpsoriasisnetwork.com/psoriasis-treatment/topicals/
  49. Mason AR, et al. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev 2013;3:CD005028.
  50. Augustin M, et al. Topical long-term therapy of psoriasis with vitamin D(3) analogues, corticosteroids and their two compound formulations: position paper on evidence and use in daily practice. J Dtsch Dermatol Ges 2014;12:667–82.
  51. Paul C, et al. Evidence-based recommendations on topical treatment and phototherapy of psoriasis: systematic review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol. 2012;26(Suppl 3):1–10.
  52. Imafuku S, Zheng M, Tada Y, et al. Asian consensus on assessment and management of mild to moderate plaque psoriasis with topical therapy. J Dermatol. 2018;45(7):805–811.
  53. Nast A, et al. S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges 2012;10Suppl 2:S1-95
  54. NCT03402828. 2019. https://clinicaltrials.gov/ct2/show/NCT03402828
  55. NCT02935582. 2019. https://clinicaltrials.gov/ct2/show/NCT02935582
  56. Rogalski C. Calcipotriol/betamethasone for the treatment of psoriasis: efficacy, safety, and patient acceptability. Psoriasis: Targets and Therapy 2015;5:97–107.
  57. Segaert S, et al. The biological rationale for use of vitamin d analogs in combination with corticosteroids for the topical treatment of plaque psoriasis. J Drugs Dermatol. 2013;12:e129-37.
  58. Sticherling M, et al. Practicability of combined treatment with calcipotriol/betamethasone gel (Daivobet(R) Gel) and improvement of quality of life in patients with psoriasis. J Dtsch Dermatol Ges 2013;11:420–7.
  59. Mrowietz U, et al. Effective treatment and improvement of quality of life in patients with scalp psoriasis by topical use of calcipotriol/betamethasone (Xamiol(R)-gel): results. J Dtsch Dermatol Ges 2011;9:825–31.
  60. Reich K, et al. Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective study. J Eur Acad Dermatol Venereol 2015;29:1156–63.
  61. Neri L, Miracapillo A. Treatment adherence and real-life effectiveness of topical therapy in patients with mild or moderate psoriasis: uptake of scientific evidence in clinical practice and dermatologists’ preferences for alternative treatment options. G Ital Dermatol Venereol 2015;150:19–26.
  62. Dauden E, et al. Expert recommendations: the use of the fixed combination calcipotriol and betamethasone dipropionate gel for the topical treatment of psoriasis. J Eur Acad Dermatol Venereol 2014;28 Suppl 2:22–32.
  63. Menter A, et al. Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial. J Drugs Dermatol 2013;12:92–8.
  64. Storm A, et al. One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic. J Am Acad Dermatol 2008;59:27–33.
  65. Basse LH, et al. Enhanced in vitro skin penetration and antipsoriatic effect of fixed combination calcipotriol plus betamethasone dipropionate in an innovative foam vehicle. J Invest Dermatol 2014; 134: 33.
  66. Lind M, et al: Supersaturation of calcipotriene and betamethasone dipropionate in a novel aerosol foam formulation for topical treatment of psoriasis provides enhanced bioavailability of the active ingredients. Dermatol Ther (Heidelb) 2016; 6: 413–425.
  67. Menter A, et al. Fixed-Combination Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam Is Well Tolerated in Patients with Psoriasis Vulgaris: Pooled Data from Three Randomized Controlled Studies. Skinmed. 2017;15:119-24
  68. Bergstrom KG, et al. Medication formulation affects quality of life: a randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. Cutis. 2003;72:407-11.
  69. Housman TS, et al. Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis. 2002;70:327-32.
  70. Lebwohl M, et al. A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Int J Dermatol. 2002;41:269-74.
  71. Stein L. Clinical studies of a new vehicle formulation for topical corticosteroids in the treatment of psoriasis. J Am Acad Dermatol. 2005;53(1 Suppl 1):S39-49.
  72. Stein LF, et al. Betamethasone valerate foam for treatment of nonscalp psoriasis. J Cutan Med Surg. 2001;5:303-7.
  73. Franz TJ, et al. Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol. 1999;38:628-32.
  74. Koo J, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study. J Dermatolog Treat. 2016;27:120-7.
  75. Leonardi C, et al. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST). J Drugs Dermatol. 2015;14:1468-77.
  76. Paul C, et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol. 2017;31:119-26.
  77. Lebwohl M, et al. Fixed Combination Aerosol Foam Calcipotriene 0.005% (Cal) Plus Betamethasone Dipropionate 0.064% (BD) is More Efficacious than Cal or BD Aerosol Foam Alone for Psoriasis Vulgaris: A Randomized, Double-blind, Multicenter, Three-arm, Phase 2 Study. J Clin Aesthet Dermatol. 2016;9:34-41.
  78. Jalili A, et al. Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam. J Eur Acad Dermatol Venereol. 2019;33:709-17.
  79. Patel DS, et al. Improvements In Efficacy And Lesion Quality In Scalp Plaque Psoriasis With Fixed Combination Calcipotriene And Betamethasone Dipropionate (cal/bd) Foam Treatment [abstract/poster No. 9803]. American Academy of Dermatology Annual Meeting: Washington, DC, USA; 2019. 1–5 March 2019.
  80. Devaux S, et al. Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2012; 26(Suppl 3): 61–67.
  81. Leonardi C et al. Poster presented at 23rd World Congress of Dermatology; Vancouver, Canada, 8–13 June 2015.
  82. Gerdes S, et al. Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: a review of realworld evidence (RWE). J Dermatolog Treat. 2020 Jan 28:1-11.
  83. Gerdes S, et al. Prospective, Observational, Non-Interventional, Multicentre Study on the Efficacy and Tolerability of a New Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in Patients with Plaque Psoriasis under Daily Practice Conditions. Dermatology. 2017;233:425-34.
  84. Wu JJ, et al. Real World Experience with Calcipotriene and Betamethasone Dipropionate Foam 0.005%/0.064% (Cal/BD Foam) in the Treatment of Adult Psoriasis Including Psoriasis Itch from Retrospective Chart Review. Value in Health. 2018. https://doi.org/10.1016/j.jval.2018.04.1623.
  85. Velasco M, et al. Patient and physician satisfaction with calcipotriol and betamethasone dipropionate aerosol foam in the treatment of plaque psoriasis on the body. Actas Dermosifiliogr. 2019;110:752–58.
  86. Anderko M, et al. Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam For Scalp Psoriasis. Clin Cosmet Investig Dermatol. 2019;12:699-705.
  87. Duvetorp A, et al. A Cost-utility Analysis of Calcipotriol/Betamethasone Dipropionate Aerosol Foam versus Ointment for the Topical Treatment of Psoriasis Vulgaris in Sweden. Acta Derm Venereol. 2019;99:393-99.
  88. Lanati EP, et al. Budget Impact Analysis of Enstilar® for The Treatment of Psoriasis In Italy. Value in Health. 2017. https://doi.org/10.1016/j.jval.2017.08.2387
  89. Asche CV, et al. Budget impact model in moderate-to-severe psoriasis vulgaris assessing effects of calcipotriene and betamethasone dipropionate foam on per-patient standard of care costs. J Med Econ. 2017;20:1000-06.
  90. Iversen L, et al. Topical treatment of psoriasis: questionnaire results on topical therapy accessibility and influence of body surface area on usage. J Eur Acad Dermatol Venereol. 2017;31:1188-1195.
  91. Bagel J, et al. A Prospective, Open-Label Study Evaluating Adjunctive Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Psoriasis Patients With Inadequate Response to Biologic Therapy. J Drugs Dermatol. 2018;17:845-50.
  92. Amat-Samaranch V, et al. Safety of calcipotriene and betamethasone dipropionate foam for the treatment of psoriasis. Expert Opin Drug Saf. 2020 Apr 3. doi: 10.1080/14740338.2020.1749594.
  93. DermNet NZ. Calcipotriol/betamethasone dipropionate foam. October 2019. https://dermnetnz.org/topics/calcipotriolbetamethasone-dipropionate-foam/
  94. LEO Pharma DermaWorld. https://uk.dermaworld.eu/treatments/enstilar/formulation/
  95. BPAC. Chronic plaque psoriasis: an overview of treatment in primary care. 2017. https://bpac.org.nz/2017/psoriasis-1.aspx.
  96. Bewley AP, et al. Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison. J Eur Acad Dermatol Venereol. 2019;33:1107-11
‹Previous Next›